Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$103.95 USD

103.95
4,455,672

-0.28 (-0.27%)

Updated May 24, 2024 04:00 PM ET

After-Market: $103.94 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Abiomed's Latest Regulatory Progress Boosts Impella Line

We believe that robust demand for Impella products will continue to drive Abiomed's (ABMD) top line over the long term.

    Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

    The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.

      Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod

      Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest U.K. national reimbursement grant.

        4 Top MedTech Stocks for Dividend Investors in 2017

        Dividend stocks are always investors' preferred choice as they provide steady income and cushion against market risks.

          Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

          Abbott's (ABT) recent FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device has boosted investor confidence.

            Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead

            The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.

              Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod

              Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.

                Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm

                Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.

                  Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm

                  Abbott Laboratories' (ABT) receipt of FDA approval for its Full MagLev HeartMate 3 LVAD strengthens one of its major business segments.

                    Agilent (A) Sues Former Employees for Infringing IP Rights

                    Agilent Technologies has sued its former employees who formed Shanghai Echrom Electronic Technology Co.

                      Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report?

                      Abbott Laboratories (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Abbott-North West London Pathology Expand in Diagnostics

                        Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.

                          The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger

                          The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger

                            Swarup Gupta headshot

                            Profit from the Dollar's Dip with These 5 S&P 500 Stocks

                            Companies with significant overseas exposure stand to gain from the dollar's dip.

                              Company News for July 21, 2017

                              Companies In The News are: ABT,KMI,PM,TRV

                                Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up

                                Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.

                                  Abbott (ABT) Tops Earnings Estimates in Q2, Misses on Sales

                                  Abbott Laboratories (ABT) gains on strong Q2 performance. Raised guidance buoys optimism.

                                    Tracey Ryniec headshot

                                    The Hottest Earnings Charts of the Week

                                    It's not easy to beat on earnings nearly every quarter but these 5 companies are doing it.

                                      Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More

                                      The market remained jittery towards medical space due to uncertainties surrounding the future of the healthcare act.

                                        Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?

                                        Abbott Laboratories (ABT) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20.

                                          Abbott Partners Bigfoot Biomedical to Expand in Diabetics

                                          Illinois-based global medical device company Abbott Laboratories (ABT) partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market.

                                            Edwards Emerges Strong on FDA Nods, International Prospect

                                            On Jul 11, we issued an updated research report on the leading molecular diagnostic company, Edwards Lifesciences Corporation (EW).

                                              LabCorp Diagnostics Strong on Novant Health Deal Extension

                                              Laboratory Corporation of America Holdings (LH), also referred to as LabCorp, has decided to extend its Technical Services Agreement with Novant Health which was originated in 2012.

                                                Medtronic (MDT) Launches Resolute Onyx DES Device in Japan

                                                Medtronic plc (MDT), a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest revenue grossing Cardiovascular segment.

                                                  Thermo Fisher at a 52-Week High: What's Driving the Stock?

                                                  Share price of Thermo Fisher Scientific Inc. (TMO), headquartered in Waltham, MA, scaled a new 52-week high of $177.99 on Jul 7, eventually closing a shade lower at $177.49.